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structions; HDRS total score was correlated to the score in
each SF-36 dimension using Pearson correlation coefficients.
Mean scores of the two categories (depressed, not de-
pressed) were compared with the norm using analysis of co-
variance allowing for effects due to age.
RESULTS: Forty specialists enrolled 663 pts (653 fully
evaluable). Mean age was 35, mean age at diagnosis was
19. Duration of untreated migraine ranged from 4 to 72
hours (82% of pts); migraine was severe in 57.3% of
cases, and throbbing in 78.9%. HDRS scores revealed a
prevalence of depression of 38.9% (HDRS score greater
than 7) among them, although 53.7% suffered from mi-
nor depression. Correlations between HDRS and SF-36
dimensions ranged, in absolute value, from 0.37 to 0.67.
All SF-36 mean scores of depressed pts were significantly
lower than the norm (P  .01). Among not depressed pts,
four out of eight mean scores are significantly lower than
norm (P  0.01).
CONCLUSION: Results of our survey suggest that a
number of women suffering from menstrual migraine are
depressed. A significant role in worsening QoL is played
by depression.
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MS is the most common neurological disorder among
young adults affecting around 85,000 people in the UK.
Copaxone is a non-interferon disease-modifying agent,
indicated to reduce the frequency of relapses in ambula-
tory patients with active RRMS.
OBJECTIVE: Demonstrate cost-effectiveness based upon
proven economic methodologies.
METHODS: An economic model was developed based
on available data (published efficacy over two and six
years and data on file over eight years) for Copaxone. Di-
rect medical and caregiver costs were taken from the pub-
lished literature. The annual cost of Copaxone is £6,650.
Rather than modeling based upon a hypothetical cohort,
the analysis was developed using patient data from the
trial where possible. The model utilizes the core end-
points of the trial, including number of relapses, disabil-
ity burden via EDSS (Expanded Disability Status Scale) at
each study visit, percentage of patients with improved
EDSS, patients without worsening of EDSS, and without
sustained progression.
RESULTS: Based upon analysis over eight years, cost per
relapse avoided and cost per disability unit avoided were
£11,208 and £9,035 respectively. Dependent on the as-
sumption regarding utility loss during a relapse (two
months with utility loss of 0.083, or six months with a
utility loss of 0.4, and a factor for severity of relapse) the
cost per QALY was between £65,896 and £23,026 re-
spectively. Sensitivity analysis showed these results were
most influenced by changes in the duration of analysis,
utility loss of relapse, and cost of therapy.
CONCLUSIONS: Previous cost-effectiveness analyses for
Copaxone reported in the literature assumed parity price
with the beta-interferons, and did not incorporate new ev-
idence of long-term efficacy. Using this new information,
the reported cost-per-QALY ratio is favourable compared
to accepted standards for cost-effectiveness in the UK.
This analysis provides economic justification for the pre-
scribing of Copaxone to appropriate patients with RRMS.
